Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are antibodies specific for CLL-1.
Core Innovation
The invention relates to C-type lectin like molecule 1 (CLL-1), also referenced as CLEC12A/DCAL-2/MICL, as a myeloid/AML/CSC marker. The disclosed antibodies are CLL-1-specific and bind with high-affinity to human and cynomolgus CLL-1. The disclosure identifies antibody clones by variable/CDR sequence sets and defines epitopes involving stalk+lectin regions of CLL-1 domains, including the C-lectin domain and stalk domain.
The disclosed antibodies are defined by specific heavy chain complementarity determining regions (CDRs) and light chain CDRs using SEQ ID NOs. The antibody binding breadth and functional performance are reported across AML samples, including binding to CD34+CD38− populations associated with LSC/CSC. The disclosure further reports potent activity in functional formats including ADC/CDC/ADCC against CLL-1-expressing AML cells, with reported binding/efficacy benchmarks.
The disclosure also reports in vivo tumor burden reduction in AML xenograft models using CLL-1-targeting antibodies. Diagnostic or monitoring use cases are described for detecting CLL-1-expressing cells. Therapeutic use is described in terms of inhibition of AML growth and selectivity versus normal CD34+ HSCs, using antibody formats including mouse and chimeric human antibodies, and ADC formats including saporin.
Claims Coverage
The partial set includes one independent claim directed to a CLL-1 binding antibody selected from three alternative CDR-defined heavy/light chain combinations, yielding three inventive feature sets defined by specific SEQ ID NO CDRs.
Cll-1 cdr-defined antibody binding using specified heavy and light cdr seq id sets
An antibody that binds to human C-type lectin like molecule 1 (CLL-1), selected from an antibody comprising heavy chain complementarity determining regions (CDRs) of SEQ ID NOs:51, 59, and 67, and light chain CDRs of SEQ ID NOs:75, 83, and 91; or an antibody comprising heavy chain CDRs of SEQ ID NOs:52, 60, and 68, and light chain CDRs of SEQ ID NOs:76, 84, and 92; or an antibody comprising heavy chain CDRs of SEQ ID NOs:53, 61, and 69 and light chain CDRs of SEQ ID NOs:77, 85, and 93.
Across the independent claim, the coverage focuses on a CLL-1 binding antibody whose binding specificity is defined by the combination of specified heavy chain CDR SEQ ID NO sets with specified light chain CDR SEQ ID NO sets, with three alternative CDR combinations provided for selection.
Stated Advantages
Potent ADC/CDC/ADCC activity against CLL-1-expressing AML cells, with reported Kd and EC50 benchmarks.
In vivo tumor burden reduction in AML xenograft models.
Selectivity versus normal CD34+ HSCs is reported.
Documented Applications
Detecting CLL-1-expressing cells for diagnostic or monitoring use cases by using a CLL-1-binding antibody.
Therapeutic use for inhibiting AML growth using CLL-1 targeting antibodies, including ADC format (e.g., saporin) and other functional formats (ADC/CDC/ADCC).
Measuring whether a cell expresses CLL-1 by contacting the cell with the antibody and detecting antibody binding to indicate CLL-1 expression.
Interested in licensing this patent?